This is an Open Access article distributed under the terms of the Creative Commons Attribution License (
In the search for generic expression strategies for mammalian protein families several bacterial expression vectors were examined for their ability to promote high yields of soluble protein. Proteins studied included cell surface receptors (Ephrins and Eph receptors, CD44), kinases (EGFR-cytoplasmic domain, CDK2 and 4), proteases (MMP1, CASP2), signal transduction proteins (GRB2, RAF1, HRAS) and transcription factors (GATA2, Fli1, Trp53, Mdm2, JUN, FOS, MAD, MAX). Over 400 experiments were performed where expression of 30 full-length proteins and protein domains were evaluated with 6 different N-terminal and 8 C-terminal fusion partners. Expression of an additional set of 95 mammalian proteins was also performed to test the conclusions of this study.
Several protein features correlated with soluble protein expression yield including molecular weight and the number of contiguous hydrophobic residues and low complexity regions. There was no relationship between successful expression and protein pI, grand average of hydropathicity (GRAVY), or sub-cellular location. Only small globular cytoplasmic proteins with an average molecular weight of 23 kDa did not require a solubility enhancing tag for high level soluble expression. Thioredoxin (Trx) and maltose binding protein (MBP) were the best N-terminal protein fusions to promote soluble expression, but MBP was most effective as a C-terminal fusion. 63 of 95 mammalian proteins expressed at soluble levels of greater than 1 mg/l as N-terminal H10-MBP fusions and those that failed possessed, on average, a higher molecular weight and greater number of contiguous hydrophobic amino acids and low complexity regions.
By analysis of the protein features identified here, this study will help predict which mammalian proteins and domains can be successfully expressed in
The production of purified proteins is important for several experimental approaches aimed to assign gene function including antibody generation for immunocytochemistry and immunoprecipitation studies [
There are several fall-back strategies for expression of correctly folded eukaryotic proteins in
The aim of this work was to ask if it is possible to derive some general conclusions regarding which expression strategy would most likely result in the expression of soluble, functionally active mammalian protein on a family-by-family or domain-by-domain basis. A deep-mining approach was taken to maximise the chances of successful expression by examining the soluble expression of 30 different proteins using 14 different expression vectors. This study allowed us to make several conclusions regarding the best strategies to adopt for the soluble expression of different mammalian proteins in bacteria. The conclusions were tested by the expression of an additional 95 mammalian proteins.
The 30 proteins chosen for this expression study are listed in Table
For this study a set of destination vectors were constructed by modifying pET-DEST42 (see Materials and Methods). The T7 promoter was chosen over other promoters commonly used for bacterial expression because of the high specificity and processivity of T7 RNA polymerase and the wide choice of expression strains currently available. Briefly, multicloning sites were created either 5' of the attR1 or 3' of the attR2 recombination sites for insertion of DNA inserts encoding N or C-terminal tags respectively. The expression vectors contained a T7lac promoter [
Expression plasmids generated by recombination reactions were used to transform
Looking first at the results for total (soluble and insoluble) expression, no clear patterns emerge for the various expression vectors used. With the exception of CASP2, CDKN2A, Trp53, EGFR(TK), FOS and CD44 most proteins expressed well across all expression vectors. Interesting differences are apparent however when one looks at the production of soluble protein. Using decahistidine green fluorescent protein (H10-GFP) or decahistidine glutathione-S-transferase (H10-GST) as fusion partners at the N-terminus gave poor yields of soluble intact product. This may not be because they were poor at promoting soluble expression but because they were prone to proteolysis during cell lysis reducing the yield of full-length soluble protein. A set of proteins (GFP, RAF1(Ras-bd), HRAS, mdm2(p53-bd), Ephb2(TK) and CCND2) gave high soluble expression levels in the baseline N-terminal decahistidine vector, which was not improved when expressed as decahistidine thioredoxin (H10-Trx) or decahistidine maltose binding protein (H10-MBP) fusions. The molecular weight of these proteins ranged from 9 – 35 Kda and averaged 22.8 Kda. These proteins are all expressed in the cytoplasm, have an average of 1 low-complexity region, 3.8 contiguous hydrophobic amino acids (hp_aa), pI of 6.6, grand average of hydropathicity index (termed GRAVY[
Comparing the 20 mammalian proteins where there are examples in all 6 expression vectors the average yields of soluble protein for the H10, H10-GFP, H10-GST, H10-Trx and H10-MBP tags are 3.3, 1.0, 1.4, 6.0 and 5.8 mg per litre of culture. This ranks the ability of the tag fusions to produce full-length soluble protein as H10-Trx ~ H10-MBP > H10 > H10-GST > H10-GFP. The pDEST17 vector (which encodes a H6 tag) was dramatically poorer at expressing soluble protein compared with the vector pN110 (which encodes a H10 tag), with average soluble expression yields of 0.8 and 3.3 mg per litre of culture respectively. Both vectors contain T7 RNA polymerase promoters, but pN110 also contains a lac operator (lacO) downstream of the promoter and the gene encoding the lac repressor (lacI) for tighter control of gene expression. This may result in a faster rate of transcript synthesis, after induction with IPTG, and hence translation rates (due to an increased concentration of mRNA) for pDEST17 compared with pN110. If translation rate exceeds the rate of protein folding, then increased production of insoluble protein would occur.
A similar study was performed where the 30 ORFs were cloned into 8 different C-terminal tag expression vectors shown in Figure
MBP-H10 was the most effective tag at the C-terminus to promote protein solubility with an average construct full-length soluble yield of 5.0 mg/l, which compares well with an average of 5.8 mg/l when this tag is fused at the N-terminus. The order of C-terminal tags to promote soluble expression was similar for total expression: MBP-H10 > GST-H10 > V5-H6 > Dhfr-H10 ~ GFP-H10 ~ Trx-H10 > H10 ~ DHFR-H10. Thioredoxin was not as effective a solubility enhancing tag when fused at the C-terminus with an average soluble yield of only 0.7 mg/l compared with 6.0 mg/l when fused to the N-terminus.
Several correlations with protein features are seen when one groups the MPB fusions according to soluble protein expression levels. For the first group, where soluble expression levels were in the range of 5 – 50 mg/l, the average molecular weight, pI and GRAVY score were 20.6 KDa, 5.9 and -0.58 respectively. The average numbers of contiguous hydrophobic amino acids, low complexity and coiled-coil regions were 3.1, 0.56 and 0.22 respectively. The second group displayed soluble expression levels between 1 – 5 mg/l. Here, the average molecular weight, pI and GRAVY score were 25.1 KDa, 7.9 and -0.39 respectively and the average numbers of contiguous hydrophobic amino acids, low complexity and coiled-coil regions were 4.3, 0.71 and 0 respectively. The last group displayed soluble expression levels between 0 – 1 mg / l. Here the average molecular weight, pI and GRAVY score were 41.1 KDa, 6.2 and -0.51 respectively and the average numbers of contiguous hydrophobic amino acids, low complexity and coiled-coil regions were 5, 2.43 and 0.21 respectively. There were representatives of nuclear, cytoplasmic and extra-cellular proteins in all three groupings.
A diverse set of proteins were chosen to test the conclusions of this study (Table
To guide future expression strategies for new proteins, particularly regarding the choice of expressing a full-length protein in a bacterial or eukaryotic system and also where to truncate multi-domain containing proteins, it is interesting to investigate if the proteins expressed in a soluble form in this study share any common properties. Recently Goh
The present study, focused on mammalian proteins from several diverse families, examined the relationship between successful soluble expression with various protein properties. Several protein features were identified in this study to correlate with soluble expression, which had not previously been shown experimentally. For both the N and C-terminal tag expression studies it was observed that the presence of several features did not correlate with successful expression including protein pI, grand average of hydropathicity index (GRAVY) [
There was a strong correlation between successful soluble expression and molecular weight of the protein. Small proteins with an average molecular weight of 22.8 KDa did not require to be fused with solubility enhancing proteins for soluble expression whereas proteins that required to be fused with N-terminal MBP or Trx for soluble expression had an average molecular weight of 40.4 KDa and those where the addition of a N-terminal fusion could not rescue soluble expression had an average size of 51.4 KDa. The same pattern also emerged in the C-terminal fusion study. The decreasing probability of successful soluble expression of mammalian proteins with increasing molecular weight is likely due to increasing protein complexity, perhaps requiring specialised eukaryotic chaperones for folding or stabilising binding partners. The majority of proteins solubly expressed in this study contained single domains and as fusion proteins were either capable of self-folding or were folded with the aid of prokaryotic chaperones. Braun
A correlation in this study was observed between increasing numbers of contiguous hydrophobic amino (hp_aa) acids (AILFWV) and soluble expression. This ranged from an average of 3.8 hp_aa for those proteins not requiring a N-terminal fusion for high level soluble expression to 5 hp_aa for proteins requiring a N-terminal fusion for successful expression and 5.6 hp_aa where expression failed under the conditions described here. This pattern was also repeated in the C-terminal fusion study where good expression proteins had an average of 3.1 hp_aa whereas poor expression proteins had an average of 5 hp_aa. In a study of the sequences of 2753 non-membrane proteins it was found that the sequences of three or more consecutive hydrophobic residues are suppressed in globular proteins [
Some interesting conclusions were drawn when soluble expression was measured for an additional set of 95 mammalian proteins expressed as H10-MBP fusions (Table
There have been three comparative studies recently where sets of proteins were cloned into several expression vectors and the effects of the fusion partner on total and soluble expression yield were examined. Hammarstrom
In this study it was found that, on average, N-terminal fusion partners are preferable for optimal protein expression. When proteins are expressed with their native N-terminus, as in our C-terminal fusion proteins, total expression levels can be more variable than when expressed with a constant N-terminal tag. This may be because of variable RNA secondary structures in the region around the start codon which could interfere with ribosome binding. An additional explanation is that during translation the expressed protein emerges from the ribosome first and initiates an incorrect, irreversible, folding pathway before the soluble fusion partner has been translated and folded. The mis-folded protein would be ubiquitin labelled and targeted to the proteasome for degradation resulting in lower total expression levels. This scenario is more likely when expressing mammalian proteins in a bacterial system which lacks specific eukaryotic chaperone proteins. It has been shown previously that proteins prone to mis-folding and aggregation can arrest GFP folding when fused at the C-terminus [
It was found that Trx and MBP were the best N-terminal protein fusions to promote protein solubility. The best C-terminal fusion to promote protein solubility was MBP and this may be acting as a true intra-molecular chaperone [
It must be stressed here that although protein solubility is a useful indicator of correct folding, additional measurements need to be performed to give supporting evidence for correct folding. These may include removing the protein fusion with a protease and analysis of the cleaved protein of interest by a variety of biophysical and functional assays such as analysis of monodispersity by light scattering [
GFP did not significantly enhance soluble protein expression when fused to the C-terminus of the proteins in this study, supporting the use of this tag as an indicator of soluble protein expression of fused ORFs.[
What guidelines have emerged from this study in developing a strategy for the production of soluble mammalian proteins in
Oligonucleotides were synthesised by Qiagen-Operon (Cologne, Germany) or Sigma-Genosys (Haverhill, UK). All restriction enzymes were from New England Biolabs (Hitchin, UK). The vectors pET-DEST42, pDEST17 and pDONR201 and
To prepare pET-DEST42-MCS, a multi-cloning site was inserted into pET-DEST42 (Invitrogen) at nt396, between the shine-dalgarno sequence and the attR1 recombination site, encoding the recognition sequences for NdeI, KpnI, DraIII and BfrBI. Inverse or whole plasmid PCR was performed on pET-DEST42 with 5'-phosphorylated PAGE purified primer pairs 20 (5' TACCCACGAAGTGATGCATACAAGTTTGTACAAAAAAGCTGAACG 3') and 21 (5' CCCATATGTATATCTCCTTCTTAAAGTTAAACAAAATTATTTCTAGAG 3') in a 20 μl reaction containing 10 ng pET-DEST42, 0.3 μM primers 20 and 21, 20 mM Tris-HCl (pH 7.5), 0.5 mM DTT, 200 μM each of dATP, dCTP, dGTP and dTTP, 1 mM MgSO4, and 0.5 unit KOD hot start DNA polymerase (Novagen). PCR cycling conditions were: 94°C – 2 mins followed by 15 cycles of 94°C – 15 s, 59°C – 30 s, 68°C – 9 mins. The 7468 bp PCR product was purified using a PCR purification spin column (Qiagen) and eluted with 30 μl of 10 mM Tris-HCl (pH8.5), digested with 20 units of DpnI enzyme at 37°C for 4 hrs, to remove methylated plasmid DNA, purified by spin column and an intramolecular ligation reaction performed using 16 ng of linear PCR product and 5 units T4 DNA ligase and the buffers from the rapid ligation kit (Roche). The ligated PCR product was used to transform
pDEST-C101 was designed to insert a decahistidine encoded sequence between the attR2 recombination site and T7 transcription termination region. pDEST-C102 is as C101 except a DraIII, BfrBI site was inserted downstream of the attR2 recombination site. Inverse PCR was performed as described above with primer pairs 1 (5' pCACCATCACCATCATCACCATCACCATTGAGTTTGATCCGGC) and 2 (5' pATGCACCACTTTGTACAAGAAAGCTGAAC) to generate pDEST-C101 and primer pairs 1 and 3 (5' pATGCATACCACTCACTTCGTGCACCACTTTGTACAAGAAAGCTGAAC) to prepare pDEST-C102. Murine and human dihydrofolate reductase (Dhfr and DHFR respectively) inserts flanked by a 5' DraIII site and blunt end at the 3' were amplified from MGC clones using the primer pairs 82 (5' TTATTACACGAAGTGCGACCATTGAACTGCATCGTCGCCGTG) and 83 (5' pGTCTTTCTTCTCGTAGACTTCAAACTTATAC 3') for Dhfr and 80 (5' TTATTACACGAAGTGGGTTCGCTAAACTGCATCGTCGCTGTG) and 81 (5' pATCATTCTTCTCATATACTTCAAATTTG) for DHFR. The DraIII digested inserts were ligated with DraIII, BfrBI digested pDEST-C102 vector to create pDEST-C102-MBP, GFP, GST, Trx, Dhfr and DHFR as shown in Figure
A nested PCR strategy was used to isolate protein encoding ORFs directly from cDNA adapted for GATEWAY cloning from the method described by J. E. Collins
All BL21(DE3) transformants were selected and propagated in the presence of 100 μg/ml ampicillin. A single antibiotic resistant colony was used to inoculate 0.5 ml 2xYT media in a 96-deep well block containing the appropriate antibiotics and shaken at 210 rpm at 37°C. When the average OD600 had reached 1 (3 hrs for BL21(DE3)), 60 μl was transferred to 1.2 ml 2xYT media in a 96-deep-well block containing the appropriate antibiotics, placed on a shaking incubator at 37°C and when the OD600 reached 0.5 (2 hrs for BL21(DE3)) IPTG added to a final concentration of 1 mM and shaking continued at 25°C for 12 hours. Total protein was analysed by transferring a 20 μl aliquot of the induced culture to a 96-well PCR plate containing 20 μl of 2 × NuPage LDS loading buffer (Invitrogen), 0.1 M DTT, heated to 95°C for 10 mins and cooled on ice prior to loading 10 μl on a 17-well 4–12 % NuPAGE Bis-Tris gels with a multi-channel gel loading syringe (Hamilton). Soluble protein was extracted by transferring 290 μl of induced culture to a shallow well plate, centrifugation at 3000 g for 5 mins, supernatant removed and cells were resuspended in 58 μl BugBuster containing 1.4 units of benzonase and 58 units of recombinant lysozyme (Novagen). For the C-terminal tag and expression strain comparison this buffer was also supplemented with 0.58 μl protease inhibitor cocktail set III 10-fold diluted in DMSO (Novagen). The cell-pellets were resuspended with a multi-channel pipette and incubated with slow shaking for 20 mins at room temperature prior to transfer to 96-well multiscreen-DV durapore filter plates with 0.65 μm pore size (Millipore). The filter plate was placed on top of a shallow 96-well plate and centrifuged at 1000 g for 2 mins. 4 μl of the filtrate was then added to a 96-well plate containing 5 μl of 4 × NuPage LDS loading buffer (Invitrogen), 11 μl of 182 mM DTT, the plate heated at 95°C for 5 mins and loaded onto a 17-well 4–12 % NuPAGE Bis-Tris gel. A His-tagged molecular weight ladder (Qiagen) was also loaded onto each gel. Gel electrophoresis and electro-transfer to PVDF membrane was as described.[
MRD performed the molecular biology, participated in the bioinformatics, expression screening, quantitation, experimental design and drafted the manuscript. SPS and RLP participated in the expression screening and quantitation. KJV helped with the bioinformatics (database searching, protein domain annotation and primer design). JM participated in the experimental design, coordination and helped to draft the manuscript. All authors approved the final manuscript.
We thank Pascal Braun and Josh LaBaer (Harvard Institute of Proteomics, Cambridge, USA) for providing some entry clones containing full length human open reading frames used in this study, Geoff Waldo (Los Alamos National Laboratory, USA) for providing a plasmid containing cycle 3 mutated GFP and John Collins and Ian Dunham (The Wellcome Trust Sanger Institute, UK) for sharing their cDNA isolation protocol. This work was supported by The Wellcome Trust.
Proteins for expression study with selected features
| No | Proteina | Domainb | Constructc | Organismd | Protein Familye | MW (Kda) | pI | Cys % | GRAVYf | hp_aag | Sub-cellular Location | LCh | CCi |
| 26 | CASP2 | FL | 1–435/435 | Hs | CARD, Peptidase_C14 | 48.9 | 6.3 | 4.1 | -0.30 | 5 | Cytoplasm | 1 | 0 |
| 24 | CCND2 | FL | 1–289/289 | Hs | cyclin, cyclin_C | 33.1 | 4.9 | 4.1 | -0.21 | 4 | Cytoplasm | 2 | 0 |
| 29 | CD44 | FL | 1–742/742 | Hs | Xlink, Pfam-B × 9 | 81.6 | 5.0 | 1.2 | -0.77 | 10 | Extra-cellular | 9 | 0 |
| 22 | CDK2 | FL | 1–298/298 | Hs | pkinase | 33.9 | 8.9 | 1 | -0.08 | 4 | Cytoplasm | 0 | 0 |
| 23 | CDK4 | FL | 1–303/303 | Hs | pkinase | 33.7 | 6.6 | 1.3 | -0.17 | 4 | Cytoplasm | 0 | 0 |
| 25 | CDKN1B | FL | 1–198/198 | Hs | CDI, Pfam-B × 2 | 22.1 | 6.6 | 2 | -1.26 | 2 | Cytoplasm | 0 | 1 |
| 28 | CDKN2A | FL | 1–156/156 | Hs | ank | 16.5 | 5.4 | 0.6 | -0.23 | 4 | Cytoplasm | 0 | 0 |
| 6 | Efna1 | FL | 18–205/205 | Mm | Ephrin | 21.9 | 6.4 | 2.1 | -0.59 | 8 | Extra-cellular | 1 | 0 |
| 7 | Efna1 | EC | 18–154/205 | Mm | Ephrin | 16.2 | 6.5 | 2.9 | -0.86 | 2 | Extra-cellular | 0 | 0 |
| 5 | Efnb2 | EC1 | 29–176/336 | Mm | Ephrin | 16.6 | 5.3 | 2.7 | -0.47 | 3 | Extra-cellular | 0 | 0 |
| 4 | Efnb2 | EC2 | 29–210/336 | Mm | Ephrin | 20.1 | 8.6 | 2.2 | -0.64 | 3 | Extra-cellular | 0 | 0 |
| 15 | EGFR | TK | 694–1022/1210 | Hs | Pkinase, Pfam-B | 37.3 | 5.5 | 1.8 | -0.22 | 3 | Cytoplasm | 1 | 0 |
| 8 | Epha2 | LB | 24–206/977 | Mm | EPH_lbd | 21.1 | 4.7 | 2.7 | -0.30 | 4 | Extra-cellular | 0 | 0 |
| 1 | Ephb2 | LB | 28–210/994 | Mm | EPH_lbd | 22.5 | 5.8 | 2.2 | -0.14 | 4 | Extra-cellular | 0 | 0 |
| 3 | Ephb2 | SAM | 922–994/994 | Mm | SAM_1 | 8.3 | 4.9 | 0 | -0.03 | 2 | Cytoplasm | 0 | 0 |
| 2 | Ephb2 | TK | 595–906/994 | Mm | Pkinase | 35.3 | 5.6 | 1.6 | -0.27 | 5 | Cytoplasm | 0 | 0 |
| 10 | Fli1 | FL | 1–452/452 | Mm | Ets, SAM_PNT, Pfam-B × 5 | 51.0 | 6.6 | 0.9 | -0.79 | 3 | Nuclear | 1 | 0 |
| 19 | FOS | FL | 1–380/380 | Hs | bZIP, Pfam-B × 4 | 40.7 | 4.6 | 2.1 | -0.37 | 5 | Nuclear | 5 | 1 |
| 9 | GATA2 | FL | 1–480/480 | Hs | GATA | 50.3 | 9.7 | 2.7 | -0.51 | 13 | Nuclear | 7 | 0 |
| 30 | GFP | FL | 1–238/238 | Av | GFP | 26.9 | 5.6 | 0.8 | -0.52 | 3 | Cytoplasm | 0 | 0 |
| 14 | GRB2 | FL | 1–217/217 | Hs | SH2, SH3 | 25.2 | 5.9 | 0.9 | -0.67 | 5 | Cytoplasm | 0 | 0 |
| 17 | HRAS | FL | 1–189/189 | Hs | ras | 21.3 | 5.0 | 3.2 | -0.42 | 4 | Cytoplasm | 1 | 0 |
| 18 | JUN | FL | 1–331/331 | Hs | bZIP, Jun | 35.7 | 9.0 | 0.9 | -0.47 | 3 | Nuclear | 3 | 1 |
| 20 | MAD | FL | 1–221/221 | Hs | HLH, Pfam-B × 2 | 25.3 | 8.9 | 1.4 | -0.97 | 2 | Nuclear | 3 | 1 |
| 21 | MAX | FL | 1–160/160 | Hs | HLH, Pfam-B × 2 | 18.3 | 5.9 | 0 | -1.32 | 2 | Nuclear | 1 | 1 |
| 12 | Mdm2 | FL | 1–489/489 | Mm | SWIB, zf-RanBP, Pfam-B × 8 | 54.5 | 4.5 | 3.5 | -0.83 | 4 | Nuclear / Cytoplasm | 5 | 0 |
| 13 | Mdm2 | p53-bd | 19–230/489 | Mm | SWIB, Pfam-B × 2 | 11.7 | 8.8 | 0.5 | -0.25 | 4 | Nuclear / Cytoplasm | 3 | 0 |
| 27 | MMP1 | FL | 1–469/469 | Hs | Peptidase_M10_N, Peptidase_M10, Hemopexin | 54.0 | 6.5 | 0.6 | -0.57 | 7 | Extra-cellular | 0 | 0 |
| 16 | RAF1 | Ras-bd | 51–131/648 | Hs | RBD | 9.2 | 9.9 | 3.8 | -0.30 | 3 | Cytoplasm | 0 | 0 |
| 11 | Trp53 | FL | 1–390/390 | Mm | P53 | 43.5 | 7.0 | 3.1 | -0.59 | 3 | Nuclear / Cytoplasm | 1 | 0 |
aLocusLink symbol. bDomain: LB, ligand binding; TK, tyrosine kinase; SAM, sterile alpha motif; EC, extra-cellular; FL, full-length; bd, binding domain. cConstruct expressed numbered by amino acid position (start – finish / total). dOrganism: Mm, Mus musculus; Hs, Homo sapiens; Av, Aequoria Victoria. eProtein family nomenclature according to the Pfam database
N-Terminal fusion expression comparison
| N-TERMINAL FUSION | ||||||||||||
|
|
||||||||||||
| Protein (domain) | H6 | H10 | H10-GFP | H10-GST | H10-Trx | H10-MBP | ||||||
|
|
||||||||||||
| T | S | T | S | T | S | T | S | T | S | T | S | |
| CASP2 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.20 | 0.20 |
|
|
| CCND2 |
|
0.00 |
|
|
|
0.02 | 1.20 | 0.00 |
|
|
|
|
| CD44 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | nc | nc | 0.00 | 0.00 | 0.00 | 0.00 |
| CDK2 |
|
1.84 | 1.03 | 0.07 | nc | nc |
|
|
2.00 | 1.54 |
|
|
| CDK4 |
|
0.71 | 1.47 | 1.37 | nc | nc | 1.32 | 0.00 | nc | nc |
|
0.00 |
| CDKN1B |
|
0.17 | 0.85 | 0.31 | 1.63 | 0.57 |
|
|
|
1.69 |
|
|
| CDKN2A | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.40 | 0.32 | nc | nc |
|
0.00 |
| Efna1 | 0.00 | 0.03 | 1.50 | 1.33 |
|
0.22 |
|
0.06 | nc | nc |
|
|
| Efna1 (EC) |
|
0.05 |
|
|
|
1.71 |
|
0.07 |
|
|
|
|
| Efnb2 (EC1) |
|
0.00 |
|
1.18 |
|
0.86 |
|
1.30 |
|
|
|
|
| Efnb2 (EC2) |
|
0.04 |
|
|
|
|
|
0.00 | nc | nc |
|
|
| EGFR (TK) | 0.00 | 0.00 | 0.21 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Epha2 (LB) | nc | nc | nc | nc |
|
0.43 |
|
0.05 |
|
1.99 |
|
|
| Ephb2 (LB) |
|
0.00 | 0.66 | 0.08 |
|
0.14 |
|
0.03 |
|
|
|
|
| Ephb2 (SAM) | 0.00 | 0.00 | nc | nc |
|
|
|
|
|
1.34 | 0.00 | 0.00 |
| Ephb2 (TK) | 0.00 | 0.00 |
|
|
|
0.35 |
|
0.14 |
|
|
|
|
| Fli1 |
|
0.05 | 0.89 | 0.08 | 2.00 | 0.00 | 1.50 | 0.00 |
|
|
|
|
| FOS | 0.25 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.49 | 0.08 | 0.27 | 0.00 |
| GATA2 | 0.33 | 0.00 | 0.19 | 0.07 |
|
0.04 | 0.00 | 0.00 |
|
|
0.00 | 0.00 |
| GFP |
|
|
|
|
|
1.33 |
|
|
|
|
|
|
| GRB2 | 1.75 | 0.04 |
|
|
|
|
|
0.84 |
|
|
|
|
| HRAS |
|
0.34 |
|
|
|
0.17 |
|
0.54 |
|
|
|
|
| JUN |
|
0.00 |
|
1.09 |
|
0.00 | 1.50 | 0.00 |
|
0.41 |
|
0.22 |
| MAD |
|
0.15 |
|
1.78 |
|
0.37 |
|
0.13 |
|
|
|
|
| MAX | nc | nc |
|
1.09 |
|
1.18 | 0.00 | 0.03 |
|
|
|
|
| Mdm2 | 0.00 | 0.00 | 1.20 | 0.91 | 0.00 | 0.00 | 0.00 | 0.00 |
|
|
|
|
| Mdm2 (p53-bd) | 1.62 | 0.36 |
|
|
|
3.20 |
|
0.22 |
|
|
|
|
| MMP1 |
|
0.00 | 0.36 | 0.10 |
|
0.00 |
|
0.04 | 0.32 | 0.32 |
|
0.48 |
| RAF1 (Ras-bd) |
|
|
|
|
|
0.00 |
|
|
|
|
|
|
| Trp53 | 0.85 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| AVERAGE |
|
0.81 |
|
|
|
1.01 |
|
1.37 |
|
|
|
|
Numbers correspond to total (T) or soluble (S) expression yield (mg/l). Yields greater than 2 mg/l are in bold, nc-not cloned.
C-Terminal fusion expression comparison
| C-TERMINAL FUSION | ||||||||||||||||
|
|
||||||||||||||||
| Protein (domain) | V5-H6 | H10 | GFP-H10 | GST-H10 | Trx-H10 | MBP-H10 | Dhfr-H10 | DHFR-H10 | ||||||||
|
|
||||||||||||||||
| T | S | T | S | T | S | T | S | T | S | T | S | T | S | T | S | |
| CASP2 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| CCND2 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| CD44 | 1.37 | 0.72 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| CDK2 |
|
|
1.88 | 1.30 | 0.70 | 0.19 | 0.53 | 0.08 | 0.86 | 0.16 |
|
|
|
0.51 | 0.00 | 0.00 |
| CDK4 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.13 | 0.00 | 0.00 | 0.00 |
|
0.44 | 0.00 | 0.00 |
| CDKN1B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.59 | 0.61 | 0.00 | 0.00 |
|
0.00 |
| CDKN2A | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
|
0.56 | 0.00 | 0.00 | 0.48 | 0.22 | 0.00 | 0.00 |
| Efna1 |
|
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.24 | 0.03 |
|
1.23 | 0.00 | 0.00 |
|
0.56 |
| Efna1 (EC) | 1.71 | 0.46 |
|
0.58 | 0.25 | 0.00 |
|
0.24 |
|
0.00 |
|
|
|
0.00 | 1.10 | 1.02 |
| Efnb2 (EC1) |
|
0.37 | 0.43 | 0.04 | 0.32 | 0.04 | 0.56 | 0.00 |
|
0.00 |
|
0.80 | 0.00 | 0.24 |
|
0.00 |
| Efnb2 (EC2) |
|
0.38 | 0.52 | 0.11 | 0.54 | 0.06 | 0.00 | 0.00 |
|
0.00 |
|
1.72 |
|
0.00 | 0.00 | 0.00 |
| EGFR (TK) | 1.14 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.28 | 0.00 |
|
1.11 |
|
0.25 |
|
0.00 | 0.00 | 0.00 |
| Epha2 (LB) |
|
0.27 | 0.00 | 0.00 | 0.15 | 0.00 |
|
0.00 |
|
0.42 |
|
|
|
0.00 | 0.00 | 0.00 |
| Ephb2 (LB) |
|
|
0.00 | 0.00 | 0.00 | 0.00 | 0.64 | 0.00 |
|
0.94 |
|
|
|
0.37 |
|
0.00 |
| Ephb2 (SAM) | 0.27 | 0.03 | 0.00 | 0.00 | 0.29 | 0.08 |
|
0.00 | 0.98 | 0.10 |
|
|
|
|
|
0.00 |
| Ephb2 (TK) |
|
1.89 |
|
0.12 | 0.00 | 0.00 |
|
|
|
0.00 |
|
|
|
1.06 | 0.00 | 0.00 |
| Fli1 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
|
0.00 | 1.10 | 0.00 | 0.00 | 0.00 |
|
0.00 |
| FOS |
|
0.27 | 0.22 | 0.00 | 0.92 | 0.49 | 0.00 | 0.00 | 0.11 | 0.00 | 1.16 | 0.62 | 0.00 | 0.00 |
|
0.00 |
| GATA2 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| GFP |
|
1.38 | 1.11 | 0.67 |
|
|
|
|
|
|
|
|
|
|
|
|
| GRB2 |
|
|
0.71 | 0.17 |
|
|
|
1.70 |
|
|
|
|
|
|
1.30 | 0.00 |
| HRAS |
|
|
0.29 | 0.25 |
|
|
0.56 | 0.39 | 1.06 | 0.37 |
|
|
|
|
0.75 | 0.57 |
| JUN |
|
0.00 | 0.31 | 0.00 | 0.00 | 0.00 | 0.48 | 0.00 | 1.41 | 0.00 |
|
0.35 | 0.00 | 0.00 |
|
0.00 |
| MAD |
|
|
|
|
0.49 | 0.13 | 1.37 | 0.00 |
|
|
|
|
1.86 | 0.13 | 0.88 | 0.00 |
| MAX | 0.00 | 0.00 | 0.00 | 0.00 | 0.71 | 0.53 |
|
|
1.59 | 0.62 |
|
|
|
|
0.94 | 0.00 |
| Mdm2 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Mdm2 (p53-bd) | 1.10 | 0.25 | 0.60 | 0.14 |
|
0.33 |
|
0.47 |
|
|
|
|
|
0.83 | 0.00 | 0.00 |
| MMP1 |
|
0.85 | 0.00 | 0.00 | 0.00 | 0.00 |
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
|
0.00 | 0.52 | 0.00 |
| RAF1 (Ras-bd) | 0.48 | 0.06 | 0.00 | 0.00 | 0.45 | 0.16 | 0.96 | 0.19 |
|
0.71 |
|
1.63 |
|
1.07 | 0.00 | 0.00 |
| Trp53 | 0.52 | 0.07 | 0.00 | 0.00 | 0.00 | 0.00 | 0.23 | 0.00 |
|
0.91 |
|
|
1.40 | 0.79 |
|
0.00 |
| AVERAGE |
|
1.65 | 0.72 | 0.28 | 1.23 | 0.71 |
|
|
|
0.69 |
|
|
|
0.85 |
|
0.16 |
Numbers correspond to total (T) or soluble (S) expression yield (mg/l). Yields greater than 2 mg/l are in bold.
Expression levels of mammalian proteins expressed with N-terminal H10-MBP fusions, with selected protein features
| No. | Protein | Accession No. | PfamA Domaina | Construct | MW (kDa) | hp_aa | LC | Total Expression (mg / l) | Soluble Expression (mg / l) |
| 31 | TAL1 | P17542 | HLH | 179–331/331 | 16.5 | 3.0 | 1.0 | 13.2 | 8.3 |
| 32 | ELF1 | P32519 | Ets | 2–619/619 | 67.4 | 6.0 | 5.0 | 0.0 | 0.0 |
| 33 | ELF1 | P32519 | nab | 2–167/619 | 18.0 | 4.0 | 2.0 | 14.6 | 14.6 |
| 34 | ELF1 | P32519 | Ets | 204–619/619 | 45.4 | 6.0 | 2.0 | 0.0 | 0.0 |
| 35 | ELF1 | P32519 | na | 316–619/619 | 32.2 | 3.0 | 1.0 | 0.0 | 0.0 |
| 36 | ELF1 | P32519 | Ets | 204–306/619 | 12.1 | 6.0 | 0.0 | 65.0 | 19.3 |
| 37 | Elf1 | Q60775 | Ets | 2–612/612 | 66.1 | 6.0 | 4.0 | 24.0 | 23.5 |
| 38 | Elf1 | Q60775 | Ets | 2–306/612 | 34.0 | 6.0 | 3.0 | 60.6 | 27.2 |
| 39 | Elf1 | Q60775 | na | 2–167/612 | 17.8 | 4.0 | 2.0 | 8.6 | 8.4 |
| 40 | Elf1 | Q60775 | Ets | 204–612/612 | 44.2 | 6.0 | 1.0 | 15.5 | 10.4 |
| 41 | Elf1 | Q60775 | Ets | 204–306/612 | 12.1 | 6.0 | 0.0 | 18.5 | 12.1 |
| 42 | Elf1 | Q60775 | na | 316–612/612 | 30.7 | 3.0 | 0.0 | 0.0 | 0.0 |
| 43 | Gata1 | P17679 | GATA × 2 | 2–413/413 | 42.5 | 3.0 | 6.0 | 16.0 | 14.3 |
| 44 | Gata1 | P17679 | GATA × 2 | 2–319/413 | 33.8 | 3.0 | 5.0 | 67.0 | 15.8 |
| 45 | Gata1 | P17679 | na | 2–182/413 | 18.6 | 3.0 | 3.0 | 9.7 | 7.2 |
| 46 | Gata1 | P17679 | GATA × 2 | 191–413/413 | 23.1 | 3.0 | 5.0 | 19.7 | 9.6 |
| 47 | Gata1 | P17679 | GATA × 2 | 191–319/413 | 14.3 | 3.0 | 0.0 | 0.0 | 0.0 |
| 48 | Gata2 | O09100 | GATA × 2 | 2–480/480 | 50.3 | 5.0 | 5.0 | 0.0 | 0.0 |
| 49 | Gata2 | O09100 | na | 2–189/480 | 19.4 | 4.0 | 2.0 | 0.0 | 0.0 |
| 50 | Gata2 | O09100 | GATA × 2 | 275–480/480 | 22.4 | 5.0 | 2.0 | 0.0 | 0.0 |
| 51 | Gata2 | O09100 | GATA × 2 | 275–402/480 | 14.2 | 1.0 | 1.0 | 0.0 | 0.0 |
| 52 | Fli1 | P26323 | SAM_PNT, Ets | 2–452/452 | 50.9 | 3.0 | 1.0 | 0.0 | 0.0 |
| 53 | Fli1 | P26323 | SAM_PNT, Ets | 2–363/452 | 41.7 | 3.0 | 0.0 | 134.5 | 61.0 |
| 54 | Fli1 | P26323 | SAM_PNT | 2–198/452 | 22.2 | 3.0 | 0.0 | 121.2 | 86.8 |
| 55 | Fli1 | P26323 | SAM_PNT, Ets | 114–452/452 | 38.6 | 3.0 | 1.0 | 61.0 | 38.2 |
| 56 | Fli1 | P26323 | SAM+ETS | 114–363/452 | 29.4 | 3.0 | 0.0 | 96.5 | 73.1 |
| 57 | Fli1 | P26323 | SAM_PNT | 114–196/452 | 10.0 | 3.0 | 0.0 | 71.8 | 51.7 |
| 58 | Fli1 | P26323 | Ets | 280–452/452 | 20.1 | 3.0 | 1.0 | 28.6 | 16.3 |
| 59 | Fli1 | P26323 | Ets | 280–363/452 | 10.9 | 3.0 | 0.0 | 23.4 | 23.0 |
| 60 | Lmo2 | P25801 | LIM × 2 | 2–158/158 | 18.2 | 3.0 | 0.0 | 106.7 | 23.8 |
| 61 | Ldb1 | P70662 | LIM_bind | 2–375/375 | 42.6 | 3.0 | 2.0 | 0.0 | 0.0 |
| 62 | Ldb1 | P70662 | LIM_bind | 2–273/375 | 31.9 | 3.0 | 0.0 | 133.8 | 62.0 |
| 63 | Ldb1 | P70662 | LIM_bind | 275–375/375 | 10.5 | 2.0 | 1.0 | 2.0 | 1.7 |
| 64 | Lyl1 | P27792 | HLH | 40–278/278 | 26.2 | 3.0 | 0.0 | 3.8 | 2.6 |
| 65 | Lyl1 | P27792 | HLH | 40–215/278 | 19.6 | 3.0 | 0.0 | 4.2 | 2.5 |
| 66 | Lyl1 | P27792 | na | 40–135/278 | 10.3 | 3.0 | 0.0 | 3.6 | 1.7 |
| 67 | Lyl1 | P27792 | HLH | 150–278/278 | 14.8 | 3.0 | 0.0 | 40.1 | 32.2 |
| 68 | Lyl1 | P27792 | HLH | 150–215/278 | 8.2 | 3.0 | 0.0 | 60.3 | 20.8 |
| 69 | Ttr | P07309 | transthyretin | 20–147/147 | 13.6 | 5.0 | 0.0 | 59.2 | 49.7 |
| 70 | Pin1 | Q9QUR7 | WW, Rotamase | 2–163/163 | 18.2 | 2.0 | 0.0 | 36.9 | 19.4 |
| 71 | Whsc1 | Q7TSF5 | PHD × 2, PWWP, SET | 2–558/558 | 63.8 | 4.0 | 2.0 | 9.4 | 1.3 |
| 72 | Whsc1 | Q7TSF5 | PHD, PWWP, SET | 2–373/558 | 43.0 | 4.0 | 0.0 | 21.6 | 12.4 |
| 73 | Whsc1 | Q7TSF5 | PHD, PWWP | 2–149/558 | 17.2 | 4.0 | 0.0 | 0.0 | 0.0 |
| 74 | Whsc1 | Q7TSF5 | PWWP, SET, PHD | 70–558/558 | 56.1 | 4.0 | 2.0 | 5.1 | 2.1 |
| 75 | Whsc1 | Q7TSF5 | PWWP, SET | 70–373/558 | 35.3 | 4.0 | 0.0 | 18.2 | 17.9 |
| 76 | Whsc1 | Q7TSF5 | PWWP | 70–149/558 | 9.5 | 4.0 | 0.0 | 56.8 | 14.6 |
| 77 | Whsc1 | Q7TSF5 | SET | 249–373/558 | 14.3 | 4.0 | 0.0 | 34.7 | 22.6 |
| 78 | Maat1 | NM_024227 | na | 2–257/257 | 30.0 | 3.0 | 0.0 | 2.7 | 2.4 |
| 79 | BC031407 | NM_145596 | na | 2–630/630 | 67.3 | 6.0 | 6.0 | 0.0 | 0.0 |
| 80 | BC031407 | NM_145596 | na | 2–455/630 | 48.5 | 6.0 | 5.0 | 0.0 | 0.0 |
| 81 | BC031407 | NM_145596 | na | 2–179/630 | 19.4 | 4.0 | 1.0 | 9.6 | 8.7 |
| 82 | BC031407 | NM_145596 | na | 178–630/630 | 48.0 | 6.0 | 5.0 | 0.0 | 0.0 |
| 83 | BC031407 | NM_145596 | na | 178–455/630 | 29.1 | 6.0 | 4.0 | 0.0 | 0.0 |
| 84 | BC031407 | NM_145596 | na | 413–630/630 | 23.7 | 4.0 | 1.0 | 0.0 | 0.0 |
| 85 | Bzrp2 | P50637 | TspO_MBR | 2–169/169 | 18.7 | 4.0 | 0.0 | 0.0 | 0.0 |
| 86 | MGC19339 | NM_145954 | Aldedh | 40–486/803 | 47.0 | 5.0 | 2.0 | 37.2 | 18.7 |
| 87 | Bsg | NM_009768 | Ig × 2, V-set | 28–323/389 | 32.4 | 4.0 | 0.0 | 61.2 | 36.6 |
| 88 | Snx15 | NM_026912 | PX, MIT | 2–337/337 | 37.6 | 4.0 | 1.0 | 32.4 | 32.0 |
| 89 | Snx15 | NM_026912 | PX | 2–226/337 | 25.6 | 4.0 | 1.0 | 20.0 | 18.8 |
| 90 | Atp2b2 | Q9R0K7 | Cation_ATPase_N | 2–94/1198 | 10.4 | 2.0 | 0.0 | 42.1 | 24.7 |
| 91 | Atp2b2 | Q9R0K7 | Cation_ATPase_N | 1039–1198/1198 | 17.9 | 2.0 | 3.0 | 6.1 | 5.0 |
| 92 | cdh23 | Q99PF4 | Cadherin | 33–132/3354 | 11.1 | 4.0 | 0.0 | 174.7 | 38.8 |
| 93 | Myo15 | Q9QZZ4 | SH3_2 | 2847–2937/3511 | 9.8 | 4.0 | 0.0 | 8.6 | 0.0 |
| 94 | Myo7a | P97479 | SH3_1 | 1602–1672/2215 | 7.8 | 4.0 | 0.0 | 76.0 | 35.4 |
| 95 | tmc1 | Q8R4P5 | na | 2–193/757 | 22.9 | 3.0 | 3.0 | 0.0 | 0.0 |
| 96 | Trvp4 | NM_022017 | na | 500–718/871 | 24.6 | 9.0 | 0.0 | 0.0 | 0.0 |
| 97 | Whrn | XM_196324 | PDZ | 811–908/908 | 11.0 | 3.0 | 0.0 | 34.1 | 31.1 |
| 98 | Espn | NM_019585 | WH2 | 2–253/253 | 28.0 | 3.0 | 2.0 | 5.5 | 3.8 |
| 99 | Map2 | P20357 | Tubulin-binding | 1657–1755/1828 | 10.6 | 2.0 | 0.0 | 47.1 | 46.8 |
| 100 | Prom | O54990 | Prominin | 124–162/867 | 4.3 | 2.0 | 1.0 | 16.3 | 8.5 |
| 101 | GluR1 | P23818 | ANF_receptor | 19–538/907 | 59.0 | 4.0 | 0.0 | 0.0 | 0.0 |
| 102 | GluR2 | P23819 | ANF_receptor | 22–545/883 | 58.6 | 4.0 | 0.0 | 0.0 | 0.0 |
| 103 | Grin1 | P35438 | na | 834–938/938 | 12.0 | 5.0 | 0.0 | 13.8 | 13.8 |
| 104 | Grin2a | P35436 | na | 23–555/1464 | 59.9 | 6.0 | 0.0 | 58.5 | 8.2 |
| 105 | Grin2b | Q01097 | Lig_chan | 656–817/1482 | 18.1 | 4.0 | 0.0 | 0.0 | 0.0 |
| 106 | Dlgh2 | NM_011807 | PDZ | 419–530/852 | 11.7 | 4.0 | 0.0 | 13.8 | 13.7 |
| 107 | Dlgh4 | Q62108 | PDZ | 311–394/724 | 8.7 | 4.0 | 0.0 | 37.4 | 29.2 |
| 108 | Dlgh3 | P70175 | PDZ | 402–509/849 | 11.7 | 5.0 | 0.0 | 0.0 | 0.0 |
| 109 | Dlgh1 | U93309 | PDZ | 432–572/927 | 15.1 | 5.0 | 0.0 | 26.7 | 23.4 |
| 110 | Syngap1 | XM_139847 | RasGAP | 405–615/1318 | 23.9 | 3.0 | 0.0 | 0.0 | 0.0 |
| 111 | Grip1 | Q925T5 | PDZ | 1–112/1034 | 9.6 | 3.0 | 0.0 | 0.0 | 0.0 |
| 112 | Homer1 | Q9Z2Y3 | WH1 | 2–107/354 | 12.1 | 3.0 | 0.0 | 17.9 | 17.6 |
| 113 | Homer3 | Q99JP6 | WH1 | 2–110/356 | 39.3 | 4.0 | 0.0 | 0.0 | 0.0 |
| 114 | TtyhI | Q9EQN7 | na | 263–450/450 | 20.6 | 5.0 | 0.0 | 35.6 | 28.3 |
| 115 | 1500001H12RIKEXT2 | NM_021316 | na | 2–149/149 | 14.8 | 5.0 | 3.0 | 66.1 | 66.1 |
| 116 | Ext2 | NM_010163 | na | 99–392/718 | 33.0 | 4.0 | 0.0 | 18.5 | 3.5 |
| 117 | KIAA1136 | Q9ULT3 | na | 45–214/597 | 19.2 | 2.0 | 0.0 | 26.8 | 10.4 |
| 118 | G2 | Q12914 | na | 1046–1692/1692 | 71.3 | 5.0 | 3.0 | 0.0 | 0.0 |
| 119 | KIAA1549 | Q9HCM3 | na | 184–464/1865 | 29.5 | 5.0 | 4.0 | 3.5 | 0.0 |
| 120 | Nfkb1 | P25799 | RHD | 39–365/971 | 36.7 | 5.0 | 0.0 | 27.1 | 22.7 |
| 121 | Nfkb1 | P25799 | RHD, TIG, Ank × 6, Death | 2–971/971 | 105.5 | 7.0 | 3.0 | 0.0 | 0.0 |
| 122 | RelA-p65 | Q04207 | RHD, TIG | 18–306/549 | 32.9 | 4.0 | 0.0 | 24.1 | 18.2 |
| 123 | RelA-p65 | Q04207 | RHD, TIG | 2–549/549 | 60.0 | 5.0 | 2.0 | 0.0 | 0.0 |
| 124 | RelB | Q04863 | RHD, TIG | 102–418/558 | 35.8 | 4.0 | 0.0 | 46.0 | 25.9 |
| 125 | myog | P12979 | HLH, Basic | 2–224/224 | 25.1 | 3.0 | 1.0 | 25.8 | 12.4 |
Features listed as Table 1 except: aPfamA domains contained within expressed protein and bna – no PfamA domains annotated.